Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: AZD2265, FPI-2265

Pipeline

Phase 3: 1

Top Sponsors

AstraZeneca1

Indications

Metastatic Castration-resistant Prostate Cancer1
Cancer1

Dothan, Alabama1 trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.